论文部分内容阅读
选择140例需择期手术的2型糖尿病围手术期患者,随机分为A,B两组,每组70例,A组给予地特胰岛素联合赖脯胰岛素治疗,B组给予胰岛素泵皮下输注赖脯胰岛素。[CSⅡ]观察两组血糖控制水平,达标时间,低血糖发生率,切口感染和延迟愈合发生率及降糖费用等方面的差异。结果两组患者在血糖控制情况,低血糖发生率,切口感染和延迟愈合等方面无明显差异(P>0.05),但CSⅡ组控制血糖达标所需时间较地特胰岛素短,且地特胰岛素组治疗费用显著低于CSⅡ。结论采用地特胰岛素联合赖脯胰岛素在2型糖尿病围手术期治疗中更安全,经济,有效。
A total of 140 patients with type 2 diabetes mellitus undergoing elective surgery were enrolled in this study. Patients were randomly divided into two groups (A and B), 70 cases in each group. Group A received insulin detemir plus insulin lispro, while group B received subcutaneous infusion of insulin pump Insulin insulin. [CSⅡ] To observe the difference of blood sugar control level, standard time, incidence of hypoglycemia, incision infection and the incidence of delayed union and hypoglycemic cost. Results There was no significant difference between the two groups in terms of blood sugar control, incidence of hypoglycemia, incision infection and delayed healing (P> 0.05). However, the time required for blood sugar control in CSⅡ group was shorter than that of insulin detemir, The cost of treatment was significantly lower than CSⅡ. Conclusion It is safer, more economical and more effective to use insulin detemir combined with insulin lispro in perioperative treatment of type 2 diabetes mellitus.